

Atacept

Cat. No.:	HY-P99446
CAS No.:	845264-92-8
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Atacept (TACI-Ig) is a recombinant fusion protein containing the extracellular, ligand-binding portion of the TACI receptor and the Fc portion of human IgG. Atacept inhibits B cell stimulation by binding to B lymphocyte stimulator and a proliferation-inducing ligand. Atacept can be used in research of B-cell autoimmune disease ^{[1][2]} .																
In Vivo	<p>Atacept (TACI-Ig; 100 µg; i.p.; three times of week for 14 days; BALB/c mice) reduces mature B-cell counts and serum antibody levels in normal mice^[1].</p> <p>Atacept (TACI-Ig) inhibits the progression of disease and autoantibody titers in a mouse model of collagen-induced arthritis (CIA)^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Male DBA/1 mice with CIA models^[1]</td> </tr> <tr> <td>Dosage:</td> <td>100 µg</td> </tr> <tr> <td>Administration:</td> <td>intraperitoneal injection; three times of week for 21 days</td> </tr> <tr> <td>Result:</td> <td>Increased serum titers of anti-collagen Abs and few overt signs of disease.</td> </tr> </table> <table border="1"> <tr> <td>Animal Model:</td> <td>BALB/c mice^[1]</td> </tr> <tr> <td>Dosage:</td> <td>100 µg</td> </tr> <tr> <td>Administration:</td> <td>intraperitoneal injection; three times of week for 14 days</td> </tr> <tr> <td>Result:</td> <td>Reduced mature B cell populations but had little effect on other cell lineages. Blocked the development of B cells at the transition from T1 to T2 and the development of MZ B cells in the spleen. Decreased the serum levels of IgM about 2.3-fold.</td> </tr> </table>	Animal Model:	Male DBA/1 mice with CIA models ^[1]	Dosage:	100 µg	Administration:	intraperitoneal injection; three times of week for 21 days	Result:	Increased serum titers of anti-collagen Abs and few overt signs of disease.	Animal Model:	BALB/c mice ^[1]	Dosage:	100 µg	Administration:	intraperitoneal injection; three times of week for 14 days	Result:	Reduced mature B cell populations but had little effect on other cell lineages. Blocked the development of B cells at the transition from T1 to T2 and the development of MZ B cells in the spleen. Decreased the serum levels of IgM about 2.3-fold.
Animal Model:	Male DBA/1 mice with CIA models ^[1]																
Dosage:	100 µg																
Administration:	intraperitoneal injection; three times of week for 21 days																
Result:	Increased serum titers of anti-collagen Abs and few overt signs of disease.																
Animal Model:	BALB/c mice ^[1]																
Dosage:	100 µg																
Administration:	intraperitoneal injection; three times of week for 14 days																
Result:	Reduced mature B cell populations but had little effect on other cell lineages. Blocked the development of B cells at the transition from T1 to T2 and the development of MZ B cells in the spleen. Decreased the serum levels of IgM about 2.3-fold.																

REFERENCES

[1]. Gross JA, et, al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BlyS. Immunity. 2001

Aug;15(2):289-302.

[2]. Gross JA, et, al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature. 2000 Apr 27;404(6781):995-9.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA